The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
High complement levels in astrocyte‐derived exosomes of Alzheimer disease
Open accessAbstract
Objective: Astrocytes fulfill neuronal trophic roles normally, but are transformed in Alzheimer disease (AD) into A1‐type reactive astrocytes that may destroy neurons through unknown mechanisms. Methods: To investigate astrocyte inflammatory mechanisms, astrocyte‐derived exosomes (ADEs) were isolated immunochemically from plasma samples of AD patients and matched controls for enzyme‐linked immunosorbent assay quantification of complement proteins. Results: ADE levels of C1q, C4b, C3d, factor B, factor D, Bb, C3b, and C5b‐C9 terminal complement complex, but not mannose‐binding lectin, normalized by the CD81 exosome marker were significantly higher for AD patients (n = 28) than age‐ and gender‐matched controls (all p < 0.0001). ADE normalized levels of interleukin (IL)‐6, tumor necrosis factor‐α, and IL‐1β were significantly higher for AD patients than controls, but there was greater overlap between the two groups than for complement proteins. Mean ADE levels of complement proteins for AD patients in a longitudinal study were significantly higher (n = 16, p < 0.0001) at the AD2 stage of moderate dementia than at the AD1 preclinical stage 5 to 12 years earlier, which were the same as for controls. ADE levels of complement regulatory proteins CD59, CD46, decay‐accelerating factor (DAF), and complement receptor type 1, but not factor I, were significantly lower for AD patients than controls (p < 0.0001 for CD59 and DAF), were diminished by the AD1 stage, and were further decreased at the AD2 stage. Interpretation: ADE complement effector proteins in AD are produced by dysregulated systems, attain higher levels than in controls, and may potentially damage neurons in the late inflammatory phase of AD. Ann Neurol 2018;83:544–552
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Genomic analysis of reactive astrogliosis
Zamanian, J. L., Xu, L., Foo, L. C., Nouri, N., Zhou, L., Giffard, R. G., & Barres, B. A. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6221-11.2012 · Cited by 2,404 · cited 1×
“In contrast, A1-type reactive astrocytes lose neuronal trophic potential and instead increase expression of proinflammatory pathways as well as toxic activities that damage synapses and destroy neurons.(2,4,10,11) It is currently unclear which of the neuronal toxic mediators generated and secreted by A1-type astrocyte…”
Reactive Astrocytes: Production, Function, and Therapeutic Potential
Liddelow, S. A., & Barres, B. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.006 · Cited by 2,336
Cited by
Roles of neuropathology-associated reactive astrocytes: a systematic review
Lawrence, J. M., Schardien, K., Wigdahl, B., & Nonnemacher, M. R. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01526-9 · Cited by 433
The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications
Arranz, A. M., & De Strooper, B. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30490-3 · Cited by 334
A1/A2 astrocytes in central nervous system injuries and diseases: Angels or devils?
Fan, Y.-Y., & Huo, J. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105080 · Cited by 304
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Upadhya, R., Zingg, W., Shetty, S., & Shetty, A. K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.017 · Cited by 282
Shi, M., Chu, F., Zhu, F., & Zhu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.870517 · Cited by 275
Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 258
Self-citationGe, X., Guo, M., Hu, T., Li, W., Huang, S., Yin, Z., Li, Y., Chen, F., Zhu, L., Kang, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.017 · Cited by 242
Kapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., Tran, J., Lazaropoulos, M. P., Chawla, S., Gulyani, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2462 · Cited by 241
Self-citationJiwaji, Z., Tiwari, S. S., Avilés-Reyes, R. X., Hooley, M., Hampton, D., Torvell, M., Johnson, D. A., McQueen, J., Baxter, P., Sabari-Sankar, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27702-w · Cited by 223
New windows into the brain: Central nervous system-derived extracellular vesicles in blood
Shi, M., Sheng, L., Stewart, T., Zabetian, C. P., & Zhang, J. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.01.005 · Cited by 181
Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets
Nizami, S., Hall‐Roberts, H., Warrier, S., Cowley, S. A., & Di Daniel, E. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14618 · Cited by 147
Winston, C. N., Romero, H. K., Ellisman, M., Nauss, S., Julovich, D. A., Conger, T., Hall, J. R., Campana, W., O’Bryant, S. E., Nievergelt, C. M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01005 · Cited by 105
Further understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
Cohen, J., Mathew, A., Dourvetakis, K. D., Sanchez-Guerrero, E., Pangeni, R. P., Gurusamy, N., Aenlle, K. K., Ravindran, G., Twahir, A., Isler, D., et al. (2024) · Cells · doi:10.3390/cells13060511 · Cited by 103
“In AD patients, cross-sectional and longitudinal studies found that A1 astrocytes, which produce inflammatory complement proteins of both the classical and alternative complement pathways in astrocyte-derived exosomes (ADEs), are increased in AD patients compared to controls [33].”
ResultAstrocyte-derived extracellular vesicles: A double-edged sword in central nervous system disorders
Zhao, S., Sheng, S., Wang, Y., Ding, L., Xu, X., Xia, X., & Zheng, J. C. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.027 · Cited by 90
Biomarker potential of brain‐secreted extracellular vesicles in blood in Alzheimer's disease
Badhwar, A., & Haqqani, A. S. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12001 · Cited by 87
Extracellular Vesicle Proteins and MicroRNAs as Biomarkers for Traumatic Brain Injury
Guedes, V. A., Devoto, C., Leete, J., Sass, D., Acott, J. D., Mithani, S., & Gill, J. M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00663 · Cited by 85
“To enrich EV samples for ADEs, glutamine aspartate transporter (GLAST) antibody has been used (150).”
BackgroundMethodInfluentialThe link between neuroinflammation and the neurovascular unit in synucleinopathies
Wang, Q., Zheng, J., Pettersson, S., Reynolds, R., & Tan, E.-K. (2023) · Science Advances · doi:10.1126/sciadv.abq1141 · Cited by 81
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79
What are activated and reactive glia and what is their role in neurodegeneration?
Bennett, M. L., & Viaene, A. N. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105172 · Cited by 77
Datta, D., Leslie, S. N., Morozov, Y. M., Duque, A., Rakic, P., van Dyck, C. H., Nairn, A. C., & Arnsten, A. F. T. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1683-1 · Cited by 76
Gómez-Molina, C., Sandoval, M., Henzi, R., Ramírez, J. P., Varas-Godoy, M., Luarte, A., Lafourcade, C. A., Lopez-Verrilli, A., Smalla, K.-H., Kaehne, T., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy098 · Cited by 76
Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease
Li, T.-R., Wang, X.-N., Sheng, C., Li, Y.-X., Li, F. Z.-T., Sun, Y., & Han, Y. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111175 · Cited by 60
Cilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60
Peng, D., Wang, Y., Xiao, Y., Peng, M., Mai, W., Hu, B., Jia, Y., Chen, H., Yang, Y., Xiang, Q., et al. (2022) · Theranostics · doi:10.7150/thno.70951 · Cited by 52
Chatterjee, M., Özdemir, S., Kunadt, M., Koel‐Simmelink, M., Boiten, W., Piepkorn, L., Pham, T. V., Chiasserini, D., Piersma, S. R., Knol, J. C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13066 · Cited by 47
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39
“80 Patients in the CE 2 stage had lower levels of regulatory proteins and greater levels of complement proteins compared to those in the CE 1 preclinical stage, adding to the mounting evidence linking inflammatory chemicals in exosomes to AD by showing that levels of complement proteins in exosomes…”
BackgroundGonzález-Molina, L. A., Villar-Vesga, J., Henao-Restrepo, J., Villegas, A., Lopera, F., Cardona-Gómez, G. P., & Posada-Duque, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.593927 · Cited by 37
Wang, X., Yang, H., Liu, C., & Liu, K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1194210 · Cited by 36
“, 2016b), complement effector and regulatory proteins (Goetzl et al., 2018b; Winston et al., 2019), and some neuroinflammation-related proteins (Goetzl et al.”
BackgroundExosome-based drug delivery systems for enhanced neurological therapeutics
Vahab, S. A., V, V. K., & Kumar, V. S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01710-x · Cited by 34
Role of Glia-Derived Extracellular Vesicles in Neurodegenerative Diseases
Li, T., Tan, X., Li, S., Al-Nusaif, M., & Le, W. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.765395 · Cited by 33
Villar-Vesga, J., Henao-Restrepo, J., Voshart, D. C., Aguillon, D., Villegas, A., Castaño, D., Arias-Londoño, J. D., Zuhorn, I. S., Ribovski, L., Barazzuol, L., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.587989 · Cited by 29
APOE-Targeted Therapeutics for Alzheimer's Disease
Yassine, H. N., Hugo, C., O'Donovan, B., Stephens, I. O., Johnson, L. A., Cole, G., TCW, J., Johansson, J., Kisler, K., & Chiba-Falek, O. (2025) · The Journal of Neuroscience · doi:10.1523/jneurosci.1388-25.2025 · Cited by 20
Small extracellular vesicles as potential theranostic tools in central nervous system disorders
Guo, M., Wang, L., Yin, Z., Chen, F., & Lei, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115407 · Cited by 4
Metadata
- Authors
- Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A., & Kapogiannis, D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2018-03
- Volume
- 83
- Issue
- 3
- Pages
- 544-552
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2790294879
- Cited by
- 370
- References
- 34
- FWCI
- 21.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.